Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA creates new webpage on post-market device studies

This article was originally published in RAJ Devices

Executive Summary

The US Food and Drug Administration has launched a new webpage to inform the public about post-approval studies conducted with medical devices1. The initiative forms part of the agency's efforts to increase transparency about its processes2.

You may also be interested in...



EMA Offers ‘Dynamic Demo’ Of New Clinical Trials Portal

The European Medicines Agency will hold a webinar to explain and demonstrate specific functionalities of the new clinical trials system relevant to clinical trial sponsors. 

UK MHRA Explains Procedures For On-Site Inspections In COVID-19 Context

New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.

Canada Asks Insulin Makers To Rectify Inconsistent Product Monographs

A class review of Canadian product monographs for various insulin products has revealed inconsistencies.

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel